Recombinant Human Papillomavirus Bivalent (Type 16/18 ) Vaccine (Yuxi Zerun Biotechnology)

重组人乳头瘤病毒双价(16/18型）疫苗（玉溪泽润生物技术）

Report date: 2022/05/17 10:44:48

Base Information

Drug NameRecombinant Human Papillomavirus Bivalent (Type 16/18 ) Vaccine (Yuxi Zerun Biotechnology)
Drug Alias Name双价人乳头瘤病毒疫苗（毕赤酵母）
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Genetically engineered subunit vaccineVaccines > Biological material > Viral vaccine +[5] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsUterine Cervical NeoplasmsCervical Intraepithelial NeoplasiaPapillomavirus Infections +[4] 
Global Approved IndicationsPapillomavirus Infections
Approved Indications in ChinaPapillomavirus Infections
Original Approved Country/TerritoryMainland China
Original Approved Date2022/03/22
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesYuxi Zerun Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPT Etana Biotechnologies IndonesiaYuxi Zerun Biotechnology Co Ltd
Inactive CompaniesShanghai Zerun Biotechnology Co Ltd
Active IndicationsPapillomavirus Infections
Inactive IndicationsUterine Cervical NeoplasmsCervical Intraepithelial NeoplasiaVirus Diseases

Other Information

ATC CodeJ07BM02
Related LinksN/A